Perrigo might have been in more of a decline than the market realized when it turned down Mylan’s $26 billion offer for the company last year, said TheStreet’s TST Jim Cramer. The generic drug company reported lower-than-expected 2016 second quarter earnings and provided downbeat guidance for the year. The Allegan, MI-based drugmaker reported adjusted earnings of $1.93 per diluted share, below estimates of $1.98 per share. Revenue fell 3.3% year-over-year to $1.48 billion but beat Wall Street’s expected $1.43 billion for the quarter. For the full-year 2016, Perrigo is projecting adjusted earnings of $6.85 to $7.15 per share, lower than prior guidance of $8.20 to $8.60 per share.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
